Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET)
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
Prediabetes is associated to an increased risk of cardiovascular disease and mortality.
Although metformin can delay progression to diabetes there is a lack of RCTs evaluating the
effect of metformin on cardiovascular outcomes. MIMET aims to investigate if addition of
metformin to standard care has effects on the occurrence of cardiovascular events after acute
myocardial infarction in patients with newly detected prediabetes (identified by oral glucose
tolerance test, HbA1c or fasting glucose levels).
Phase:
Phase 3
Details
Lead Sponsor:
Karolinska Institutet
Collaborators:
Capio Sankt Görans Hospital The Swedish Research Council Uppsala University